Core Viewpoint - Sanofi has agreed to acquire UK biotech company Vicebio Ltd. for up to $1.6 billion, aiming to gain access to an experimental vaccine and technology that accelerates vaccine development [1] Group 1: Acquisition Details - The acquisition price for Vicebio Ltd. is up to $1.6 billion [1] - The deal will provide Sanofi with an experimental vaccine targeting multiple respiratory diseases, including respiratory syncytial virus (RSV) [1] Group 2: Strategic Intent - Sanofi's CEO, Paul Hudson, is actively seeking innovative solutions that align with the company's existing product portfolio [1] - The experimental vaccine from Vicebio is intended to complement Sanofi's new therapy, Beyfortus, which also targets RSV [1]